Logo image of HCP

HASHICORP INC-CL A (HCP) Stock Fundamental Analysis

NASDAQ:HCP - Nasdaq - US4181001037 - Common Stock - Currency: USD

34.78  -0.03 (-0.09%)

After market: 34.98 +0.2 (+0.58%)

Fundamental Rating

5

HCP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 282 industry peers in the Software industry. No worries on liquidiy or solvency for HCP as it has an excellent financial health rating, but there are worries on the profitability. HCP is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HCP had positive earnings in the past year.
In the past year HCP had a positive cash flow from operations.
In the past 5 years HCP always reported negative net income.
In the past 5 years HCP always reported negative operating cash flow.
HCP Yearly Net Income VS EBIT VS OCF VS FCFHCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

HCP's Return On Assets of -7.22% is in line compared to the rest of the industry. HCP outperforms 43.11% of its industry peers.
Looking at the Return On Equity, with a value of -9.72%, HCP is in line with its industry, outperforming 49.82% of the companies in the same industry.
Industry RankSector Rank
ROA -7.22%
ROE -9.72%
ROIC N/A
ROA(3y)-15.33%
ROA(5y)-17.17%
ROE(3y)-20.37%
ROE(5y)-30.92%
ROIC(3y)N/A
ROIC(5y)N/A
HCP Yearly ROA, ROE, ROICHCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Gross Margin of HCP (82.09%) is better than 86.93% of its industry peers.
HCP's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for HCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.29%
HCP Yearly Profit, Operating, Gross MarginsHCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

HCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCP has more shares outstanding than it did 1 year ago.
HCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HCP Yearly Shares OutstandingHCP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
HCP Yearly Total Debt VS Total AssetsHCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 9.80 indicates that HCP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.80, HCP belongs to the best of the industry, outperforming 85.87% of the companies in the same industry.
HCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.8
ROIC/WACCN/A
WACC13.94%
HCP Yearly LT Debt VS Equity VS FCFHCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

HCP has a Current Ratio of 3.79. This indicates that HCP is financially healthy and has no problem in meeting its short term obligations.
HCP has a better Current ratio (3.79) than 81.63% of its industry peers.
A Quick Ratio of 3.79 indicates that HCP has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.79, HCP belongs to the best of the industry, outperforming 81.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.79
HCP Yearly Current Assets VS Current LiabilitesHCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 247.62% over the past year.
HCP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.30%.
Measured over the past years, HCP shows a very strong growth in Revenue. The Revenue has been growing by 61.00% on average per year.
EPS 1Y (TTM)247.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)16.3%
Revenue growth 3Y40.14%
Revenue growth 5Y61%
Sales Q2Q%18.66%

3.2 Future

Based on estimates for the next years, HCP will show a very strong growth in Earnings Per Share. The EPS will grow by 118.92% on average per year.
Based on estimates for the next years, HCP will show a quite strong growth in Revenue. The Revenue will grow by 15.37% on average per year.
EPS Next Y509.24%
EPS Next 2Y171.61%
EPS Next 3Y118.92%
EPS Next 5YN/A
Revenue Next Year16.96%
Revenue Next 2Y15.67%
Revenue Next 3Y15.37%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HCP Yearly Revenue VS EstimatesHCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
HCP Yearly EPS VS EstimatesHCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 112.19, HCP can be considered very expensive at the moment.
HCP's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of HCP to the average of the S&P500 Index (26.25), we can say HCP is valued expensively.
The Price/Forward Earnings ratio is 71.87, which means the current valuation is very expensive for HCP.
HCP's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, HCP is valued quite expensively.
Industry RankSector Rank
PE 112.19
Fwd PE 71.87
HCP Price Earnings VS Forward Price EarningsHCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of HCP is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 124.32
EV/EBITDA N/A
HCP Per share dataHCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HCP's earnings are expected to grow with 118.92% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y171.61%
EPS Next 3Y118.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HCP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HASHICORP INC-CL A

NASDAQ:HCP (2/26/2025, 8:00:01 PM)

After market: 34.98 +0.2 (+0.58%)

34.78

-0.03 (-0.09%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-28 2025-05-28/amc
Inst Owners79.69%
Inst Owner Change-88.04%
Ins Owners3.97%
Ins Owner Change-56.62%
Market Cap7.11B
Analysts52
Price Target35.32 (1.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1179.36%
Min EPS beat(2)163.27%
Max EPS beat(2)2195.45%
EPS beat(4)4
Avg EPS beat(4)814.28%
Min EPS beat(4)163.27%
Max EPS beat(4)2195.45%
EPS beat(8)8
Avg EPS beat(8)447.11%
EPS beat(12)12
Avg EPS beat(12)310.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.35%
Min Revenue beat(2)3.98%
Max Revenue beat(2)4.72%
Revenue beat(4)4
Avg Revenue beat(4)3.95%
Min Revenue beat(4)3.32%
Max Revenue beat(4)4.72%
Revenue beat(8)8
Avg Revenue beat(8)3.78%
Revenue beat(12)12
Avg Revenue beat(12)5.75%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.2%
EPS NQ rev (1m)-2.58%
EPS NQ rev (3m)22.03%
EPS NY rev (1m)0%
EPS NY rev (3m)42.14%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)1.25%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)1.53%
Valuation
Industry RankSector Rank
PE 112.19
Fwd PE 71.87
P/S 10.86
P/FCF 124.32
P/OCF 104.53
P/B 5.65
P/tB 5.75
EV/EBITDA N/A
EPS(TTM)0.31
EY0.89%
EPS(NY)0.48
Fwd EY1.39%
FCF(TTM)0.28
FCFY0.8%
OCF(TTM)0.33
OCFY0.96%
SpS3.2
BVpS6.15
TBVpS6.05
PEG (NY)0.22
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.22%
ROE -9.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.09%
FCFM 8.73%
ROA(3y)-15.33%
ROA(5y)-17.17%
ROE(3y)-20.37%
ROE(5y)-30.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.29%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 84.44%
Cap/Sales 1.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.79
Quick Ratio 3.79
Altman-Z 9.8
F-Score6
WACC13.94%
ROIC/WACCN/A
Cap/Depr(3y)195.54%
Cap/Depr(5y)361.24%
Cap/Sales(3y)2%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)247.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y509.24%
EPS Next 2Y171.61%
EPS Next 3Y118.92%
EPS Next 5YN/A
Revenue 1Y (TTM)16.3%
Revenue growth 3Y40.14%
Revenue growth 5Y61%
Sales Q2Q%18.66%
Revenue Next Year16.96%
Revenue Next 2Y15.67%
Revenue Next 3Y15.37%
Revenue Next 5YN/A
EBIT growth 1Y37.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year118.63%
EBIT Next 3Y44.51%
EBIT Next 5YN/A
FCF growth 1Y156.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y173.12%
OCF growth 3YN/A
OCF growth 5YN/A